<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155869</url>
  </required_header>
  <id_info>
    <org_study_id>PPO 10-079</org_study_id>
    <nct_id>NCT01155869</nct_id>
  </id_info>
  <brief_title>Pilot Study of Depot NTX in Homeless Veterans</brief_title>
  <official_title>Pilot Study of Depot Naltrexone in Alcohol-Dependent, Homeless Veterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Almost 200,000 veterans are homeless each night, about one-quarter to one-third of homeless&#xD;
      adults in the U.S. Half need treatment for a substance use disorder, usually alcohol&#xD;
      dependence, but sobriety is often required to access alcohol treatment and housing services.&#xD;
      A monthly injection of depot naltrexone is efficacious in reducing alcohol use, but it is&#xD;
      expensive and restricted in many VA Medical Centers. Oral naltrexone is more available but&#xD;
      seldom used because of adherence problems that limit effectiveness. This open-label pilot&#xD;
      study would compare the effect of depot versus oral naltrexone to help twenty homeless,&#xD;
      alcohol-dependent veterans decrease their drinking, achieve sobriety and qualify for housing&#xD;
      services. This study's findings could expand access to effective medication-assisted alcohol&#xD;
      treatment in the VA, and thus help homeless veterans with alcohol problems improve their&#xD;
      drinking, housing status, and appropriate use of health services.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anticipated Impacts on Veteran's Healthcare. Ending homelessness among veterans is a major&#xD;
      priority for VA. Veterans represent between one in four and one in three homeless adults.&#xD;
      Almost 200,000 veterans are homeless each night. Rhode Island has the second highest per&#xD;
      capita concentration of homeless persons in the United States and an estimated 2,000 homeless&#xD;
      veterans. Half report unmet service needs related to substance use disorders. The VA is a&#xD;
      major service provider to homeless persons and has developed innovative housing assistance&#xD;
      programs. However, sobriety is required to access many housing services. Effective&#xD;
      medication-assisted treatment for the alcohol-dependent, homeless population could improve&#xD;
      their substance use, health care utilization and housing stability. If depot naltrexone is a&#xD;
      useful tool for engaging alcohol-dependent, homeless veterans in effective treatment, a&#xD;
      definitive study showing its effect would lead to fewer restrictions on depot naltrexone on&#xD;
      the VA formulary, and expand access to effective medication-assisted treatment.&#xD;
&#xD;
      Project Background/Rationale. A dearth of residential long-term rehabilitation beds makes an&#xD;
      initial period of sobriety necessary in order for homeless persons to access needed&#xD;
      transitional sheltering in order to participate in outpatient alcohol treatment. Many&#xD;
      alcohol-dependent homeless veterans find it difficult to achieve a period of sobriety.&#xD;
      Clinical trials suggest that depot naltrexone is more efficacious than placebo in improving&#xD;
      alcohol consumption among alcohol-dependent subjects, but depot naltrexone is expensive and&#xD;
      has limited availability in many VA Medical Centers. Oral naltrexone is widely available but&#xD;
      seldom used. This work seeks to examine the effect of depot versus oral naltrexone to help&#xD;
      homeless alcohol dependent veterans.&#xD;
&#xD;
      Project Objectives. This open-label pilot study will compare the effect of 16-weeks of depot&#xD;
      versus oral naltrexone among housing-seeking, alcohol dependent, homeless veterans. Outcomes&#xD;
      will include alcohol consumption, housing stability, emergency department and hospital&#xD;
      utilization, and substance abuse treatment participation. These preliminary data will&#xD;
      evaluate the feasibility and effect size to allow the design of a larger, more definitive&#xD;
      study of whether, compared to the oral naltrexone condition, the depot naltrexone group will&#xD;
      experience: greater proportion of days abstinent and fewer drinks per drinking day; shorter&#xD;
      time to achieve 30 days sobriety; more improvement in housing stability; fewer emergency&#xD;
      department visits and hospitalizations and greater attendance at substance abuse treatment&#xD;
      (number of visits attended).&#xD;
&#xD;
      Project Methods. Over 5 months, 20 homeless, alcohol dependent veterans will be recruited&#xD;
      from the waiting lists for transitional or permanent housing at the Providence VA Medical&#xD;
      Center. Using block randomization to stratify by current duration of abstinence (less than 7&#xD;
      days vs. 7 or more days) and sheltering (doubled-up/unsheltered/emergency vs. transitional&#xD;
      sheltered), subjects will be assigned to either injection with depot naltrexone 380 mg.&#xD;
      monthly or oral naltrexone 50 mg daily for 16 weeks. All will have medical visits with&#xD;
      medication management counseling every 4 weeks with during the treatment period. Referrals&#xD;
      will be made to needed services in keeping with standard practice. Research assessments at&#xD;
      baseline and every 4 weeks through week 24 will assess alcohol consumption through&#xD;
      self-report on calendar-based interviews, breathalyzer and liver enzyme testing. Primary&#xD;
      outcomes will be alcohol consumption and time from randomization-to-30-day-sobriety.&#xD;
      Secondary outcomes will include housing stability (across 5 ordered categories), emergency&#xD;
      department and hospital utilization, and alcohol treatment participation from administrative&#xD;
      data, CPRS abstracting and self-report.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment&#xD;
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Weekly Self-reported Alcohol Consumption</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean number of standard drinks per week during the 24 week study. A standard drink is any drink that contains about 14 grams of pure alcohol, e.g. 12 ounces of beer, 5 ounces of wine or 1.5 ounces of spirits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Participation</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percentage of total during-treatment study visits attended. This serves as a proxy for the number of months of treatment participation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>XR-NTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depot naltrexone (Vivitrol) 380 mg. IM monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Naltrexone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naltrexone 50 mg tablet PO daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depot naltrexone</intervention_name>
    <description>Depot naltrexone 380 mg. IM monthly</description>
    <arm_group_label>XR-NTX</arm_group_label>
    <other_name>Vivitrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Naltrexone</intervention_name>
    <description>Naltrexone 50 mg tablet PO daily</description>
    <arm_group_label>Oral Naltrexone</arm_group_label>
    <other_name>Revia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Homeless per the federal definition (HEARTH Act, 2009), which includes individuals who&#xD;
             lack a fixed, regular, and adequate nighttime residence; and those who have a primary&#xD;
             nighttime residence that is a supervised publicly or privately operated shelter&#xD;
             designed to provide temporary accommodations (including welfare hotels, congregate&#xD;
             shelters, and transitional housing); an institution that provides a temporary&#xD;
             residence for individuals intended to be institutionalized; and/or a public or private&#xD;
             place not designed for, or ordinarily used as, a regular sleeping accommodation for&#xD;
             human beings (including doubled up with a friend or family member).&#xD;
&#xD;
          2. Meet criteria for a DSM-IV diagnosis of alcohol abuse or dependence in the past year.&#xD;
&#xD;
          3. Last reported drink between 12 hours and 12 months prior, and BAC by breathalyzer of&#xD;
             .08 or less.&#xD;
&#xD;
          4. Age between 18 and 64 years.&#xD;
&#xD;
          5. Eligible to receive VA services.&#xD;
&#xD;
          6. Willing to provide informed consent that will include all study procedures.&#xD;
&#xD;
          7. Those who report any opiate use in the past month must pass a naloxone challenge test&#xD;
             (no sign of opiate withdrawal after IM injection of 0.8 mg naloxone).&#xD;
&#xD;
          8. If female of childbearing potential -- must be using adequate contraception.&#xD;
&#xD;
          9. Cognitively intact and showing no signs of delusional thought processes on the Short&#xD;
             Blessed test (Callahan, 2002) and SCID checklist. Those with an untreated SMI and/or&#xD;
             not capable of understanding the study due to an active cognitive impairment or&#xD;
             delusional thought process will be excluded.&#xD;
&#xD;
         10. Speak English sufficiently to understand instructions and assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Untreated disorder that might make participation hazardous (e.g. untreated psychosis&#xD;
             or bipolar disorder with mania on SCID checklist or significant suicide risk on&#xD;
             Modified Scale of Suicidal Ideation (MSSI).&#xD;
&#xD;
          2. Use of contraindicated medications such as an opioid for a documented diagnosis or&#xD;
             opiate maintenance.&#xD;
&#xD;
          3. Chronic pain condition or expected procedure during the study that is likely to&#xD;
             require opioid analgesia.&#xD;
&#xD;
          4. Contraindicated medical conditions including pregnancy/lactation; liver failure or&#xD;
             liver function test levels greater than three times normal; glaucoma; prior adverse&#xD;
             reaction to naltrexone; life expectancy of less than 6 months or medical condition&#xD;
             that will likely require skilled nursing facility care) within 6 months.&#xD;
&#xD;
          5. Stated plan to leave the area within 6 months of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter D Friedmann, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Providence</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Providence</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908-4799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Friedmann PD, Mello D, Lonergan S, Bourgault C, O'Toole TP. Aversion to injection limits acceptability of extended-release naltrexone among homeless, alcohol-dependent patients. Subst Abus. 2013;34(2):94-6. doi: 10.1080/08897077.2012.763083.</citation>
    <PMID>23577900</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 30, 2010</study_first_submitted>
  <study_first_submitted_qc>June 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2010</study_first_posted>
  <results_first_submitted>September 17, 2013</results_first_submitted>
  <results_first_submitted_qc>June 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 17, 2014</results_first_posted>
  <last_update_submitted>June 16, 2014</last_update_submitted>
  <last_update_submitted_qc>June 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alcohol dependence</keyword>
  <keyword>homelessness</keyword>
  <keyword>naltrexone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>215 potential subjects were approached over a 16-month period of recruitment; only 15 agreed to be screen after hearing of study procedures.</recruitment_details>
      <pre_assignment_details>5 were excluded (1 did not meet criteria for homelessness, 1 did not meet criteria for alcohol dependence, 1 had untreated delusional thinking, and 2 had opioid-requiring pain); 3 eligible participants did not appear for baseline interview and could not be found; only 7 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>XR-NTX</title>
          <description>Depot naltrexone (Vivitrol) 380 mg. IM monthly</description>
        </group>
        <group group_id="P2">
          <title>Oral Naltrexone</title>
          <description>Naltrexone 50 mg tablet PO daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>XR-NTX</title>
          <description>Depot naltrexone (Vivitrol) 380 mg. IM monthly</description>
        </group>
        <group group_id="B2">
          <title>Oral Naltrexone</title>
          <description>Naltrexone 50 mg tablet PO daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Weekly Self-reported Alcohol Consumption</title>
        <description>Mean number of standard drinks per week during the 24 week study. A standard drink is any drink that contains about 14 grams of pure alcohol, e.g. 12 ounces of beer, 5 ounces of wine or 1.5 ounces of spirits.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XR-NTX</title>
            <description>Depot naltrexone (Vivitrol) 380 mg. IM monthly</description>
          </group>
          <group group_id="O2">
            <title>Oral Naltrexone</title>
            <description>Naltrexone 50 mg tablet PO daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Self-reported Alcohol Consumption</title>
          <description>Mean number of standard drinks per week during the 24 week study. A standard drink is any drink that contains about 14 grams of pure alcohol, e.g. 12 ounces of beer, 5 ounces of wine or 1.5 ounces of spirits.</description>
          <units>standard drink</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="65" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Participation</title>
        <description>Percentage of total during-treatment study visits attended. This serves as a proxy for the number of months of treatment participation</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XR-NTX</title>
            <description>Depot naltrexone (Vivitrol) 380 mg. IM monthly</description>
          </group>
          <group group_id="O2">
            <title>Oral Naltrexone</title>
            <description>Naltrexone 50 mg tablet PO daily</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Participation</title>
          <description>Percentage of total during-treatment study visits attended. This serves as a proxy for the number of months of treatment participation</description>
          <units>percentage of visits</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Visits</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>XR-NTX</title>
          <description>Depot naltrexone (Vivitrol) 380 mg. IM monthly</description>
        </group>
        <group group_id="E2">
          <title>Oral Naltrexone</title>
          <description>Naltrexone 50 mg tablet PO daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>Pt missed appt for second injection and study interview. In trying to locate the subject, RA periodically checked CPRS. Record located in CPRS noted death.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <description>Emergency department visit</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only 15 of 215 alcohol-dependent, homeless veterans would consider a study that included an intramuscular injection of XR-NTX. Of 3 given XR-NTX, only 1 returned for injection #2. Aversion to injection likely contributed to poor acceptability.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Peter Friedmann</name_or_title>
      <organization>Providence VA Medical Center</organization>
      <phone>401-273-7100 ext 6240</phone>
      <email>peter.friedmann@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

